Navigation Links
Perrigo Settles Desloratadine Patent Litigation
Date:12/4/2008

ALLEGAN, Mich., Dec. 4 /PRNewswire-FirstCall/ -- The Perrigo Company (Nasdaq: PRGO; TASE) announced today that all Hatch-Waxman litigation relating to Desloratadine tablets (5 mg) has been settled with Perrigo taking a license under all relevant patents. Perrigo had been sued for patent infringement of US Patent Nos. 6100274, 7214683 and 7214684 based upon its filing of an ANDA containing a Paragraph IV certification. Under the terms of the settlement, Perrigo can commercially launch its generic Desloratadine product on July 1, 2012, or earlier in certain circumstances. The new product launch may be a prescription or over-the-counter (OTC) product depending on its status at the time of launch. The Perrigo product is awaiting FDA approval.

This product seeks an AB-rating as equivalent to Schering-Plough's Clarinex(R) tablets (5 mg) indicated for the treatment of seasonal allergic rhinitis, perennial allergic rhinitis and chronic idiopathic urticaria. Sales for the brand were approximately $300 million, according to Wolters Kluwer data for the twelve months ending October 2008.

Perrigo's Chairman and CEO Joseph C. Papa stated, "This is another example of Perrigo's continued commitment to bring new products to the market. Perrigo continues to be focused on our mission of making quality healthcare more affordable for consumers."

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products. The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of manufacturing facilities are the United States, Israel, Mexico and the United Kingdom. Visit Perrigo on the Internet (http://www.perrigo.com).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 28, 2008, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Arthur J. Shannon, Vice President, Investor Relations and Communication

(269) 686-1709

E-mail: ajshannon@perrigo.com


'/>"/>
SOURCE Perrigo Company
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Perrigo Acknowledges Settlement of NASACORT(R) AQ Nasal Spray Patent Litigation
2. Perrigo Announces FDA Tentative Approval for Ibuprofen PM
3. Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals
4. Perrigo Company To Present at the Merrill Lynch Global Pharmaceutical Conference
5. Perrigo Begins Shipments of Famotidine Complete to Customers Nationwide
6. Perrigo Company Announces Appointment of New Board Member
7. Perrigo Company to Present at The Oppenheimer & Co. Inc. 8th Annual Consumer Growth Conference
8. Perrigo Announces Approval for Rx Cetirizine Syrup
9. Perrigo Confirms Filing for Generic Version of VANOS(R)
10. Perrigo Company Announces Collaborative Agreement for Generic Topical Products With Pentech
11. Perrigo Company to Present at the Citi Investment Research Global Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... 28, 2016 , ... Amada Senior Care, premier provider of non-medical in-home care ... its San Antonio West location. Prior to entering the senior care industry, Amada franchise ... of Amada San Antonio West will take place on Friday, April 29th. ...
(Date:4/28/2016)... AZ (PRWEB) , ... April ... ... the AnzuMedical™ Knowledge Sharing and Collaboration Platform™ , today announced a ... platform will provide efficient access to medical knowledge, educational resources, and a ...
(Date:4/28/2016)... ... April 28, 2016 , ... April, ... a Top Doc in Physical Medicine and Rehabilitation by Philadelphia Magazine. , Philadelphia ... Ltd. by randomly surveying physicians and medical leadership across the country. These select ...
(Date:4/28/2016)... ... 28, 2016 , ... SyncDog, Inc. , the leading ... mobility workstation suite, SentinelSecure™, at MobileIron’s 6th annual Mobile First Conference in San ... MobileIron’s 6th Mobile First Conference and will feature immersive training, collaboration, and connections ...
(Date:4/28/2016)... ... ... The Aging in Motion Coalition (AIM) has announced the Centers for ... recognition for separate reporting and data collection. The code, M62.84, will be available for ... a combination of low muscle mass and weakness in older adults that causes functional ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... , April 27, 2016  Bayer Animal Health ... senior from the University of Florida College of ... Bayer Excellence in Communication Award (BECA). Brittany was ... were awarded a total of $70,000 in scholarship ... four years, Bayer has provided a total of ...
(Date:4/27/2016)... , April 27, 2016 ... to reach USD 2.06 billion by 2022, according ... Inc. Increasing consumer awareness towards a healthy lifestyle ... next seven years.      (Logo: ... intake coupled with rising health treatment expenditure has ...
(Date:4/26/2016)... 27, 2016 Research and Markets ... Diagnostics Market 2016-2020" report to their offering. ... global molecular diagnostics market is projected to grow at ... Molecular diagnostics is a technique that involves measurement ... level to detect changes in biochemical pathways. The aim ...
Breaking Medicine Technology: